Why IMU is a multi multi bagger, page-359

For those that doubt how much big Pharma will pay for immunotherapy drugs look at what Bristol Myers paid for Celgene last year to try and keep market share against Merk & Co (Keytruda)

(Reuters) - Bristol-Myers Squibb Co BMY.N said on Thursday it would buy Celgene Corp CELG.O for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever.
Bristol's most important cancer immunotherapy and growth driver, Opdivo, has lost much of its luster as Merck & Co's MRK.N rival drug Keytruda seized dominance in advanced lung cancer, the most lucrative oncology market. Meanwhile, Celgene has endured high-profile clinical failures and U.S. exclusivity on its flagship multiple myeloma drug, Revlimid, will start being phased out in 2022

Celgene is well ahead of IMU in that it has drugs into the market and has annual sales of about $4B USD with most of this income derived from Revlimid

However let's look at the safety profile and long list of side effects for Revlimid (including cancer)
https://themmrf.org/multiple-myeloma/treatment-options/standard-treatments/revlimid/

Any company that can come up with a good (not necessarily great) safety profile with similar efficacy in this space will be worth what?